DLX2-DT

Across TCGA pan-cancer cohorts, DLX2-DT RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of DLX2-DT’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where DLX2-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DLX2-DT is over-expressed in tumor.

HNSC, LUSC, and BRCA are the cancer types where DLX2-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DLX2-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.612	<.001	12	view →
LUSC	All	II,III,IV	+0.510	<.001	6	view →
BRCA	All	All	+0.313	<.001	6	view →
LIHC	Female	All	+0.097	.008	6	view →
BLCA	Male	All	+0.222	.001	5	view →
LUAD	All	All	+0.064	.003	5	view →
KIRC	Male	All	+0.033	<.001	4	view →
PRAD	All	All	+0.504	<.001	2	view →
UCEC	All	All	+0.282	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

DLX2-DT–HNSC

Open the HNSC breakdown →